Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 14.17
(-0.14%)
USD 14.17
(-0.14%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | - USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 881.7 Thousand USD | -77.61% |
| 2020 | 3.93 Million USD | -89.11% |
| 2019 | 36.14 Million USD | 649.51% |
| 2018 | 4.82 Million USD | 97.62% |
| 2017 | 2.44 Million USD | 27.66% |
| 2016 | 1.91 Million USD | 194.8% |
| 2015 | 648.38 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2023 Q4 | 1.34 Million USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q1 | - USD | 100.0% |
| 2022 FY | - USD | -100.0% |
| 2021 Q1 | 647.82 Thousand USD | -1.58% |
| 2021 Q2 | 136.55 Thousand USD | -78.92% |
| 2021 Q3 | 97.32 Thousand USD | -28.73% |
| 2021 FY | 881.7 Thousand USD | -77.61% |
| 2021 Q4 | -881.7 Thousand USD | -1005.96% |
| 2020 Q3 | 1.23 Million USD | 329.77% |
| 2020 Q2 | 286.34 Thousand USD | -83.75% |
| 2020 Q1 | 1.76 Million USD | -31.53% |
| 2020 FY | 3.93 Million USD | -89.11% |
| 2020 Q4 | 658.2 Thousand USD | -46.51% |
| 2019 Q3 | 2.58 Million USD | -91.1% |
| 2019 FY | 36.14 Million USD | 649.51% |
| 2019 Q1 | 1.88 Million USD | -2.16% |
| 2019 Q4 | 2.57 Million USD | -0.63% |
| 2019 Q2 | 29.09 Million USD | 1442.92% |
| 2018 Q2 | 853.64 Thousand USD | -10.18% |
| 2018 Q1 | 950.44 Thousand USD | 138.95% |
| 2018 FY | 4.82 Million USD | 97.62% |
| 2018 Q4 | 1.92 Million USD | 76.67% |
| 2018 Q3 | 1.09 Million USD | 27.79% |
| 2017 Q3 | 796.31 Thousand USD | 127.4% |
| 2017 FY | 2.44 Million USD | 27.66% |
| 2017 Q2 | 350.18 Thousand USD | -72.93% |
| 2017 Q4 | -2.44 Million USD | -406.44% |
| 2017 Q1 | 1.29 Million USD | 244.37% |
| 2016 Q3 | 742.55 Thousand USD | 87.23% |
| 2016 FY | 1.91 Million USD | 194.8% |
| 2016 Q4 | 375.67 Thousand USD | -49.41% |
| 2016 Q2 | 396.59 Thousand USD | 0.0% |
| 2016 Q1 | 396.59 Thousand USD | 8.87% |
| 2015 Q4 | 364.29 Thousand USD | 113.72% |
| 2015 Q2 | 113.63 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | 648.38 Thousand USD | 0.0% |
| 2015 Q3 | 170.45 Thousand USD | 50.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | 100.0% |
| Dynavax Technologies Corporation | 232.28 Million USD | 100.0% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 100.0% |
| Perrigo Company plc | 4.65 Billion USD | 100.0% |
| Illumina, Inc. | 4.5 Billion USD | 100.0% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 100.0% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | 100.0% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 100.0% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 100.0% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 100.0% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 100.0% |
| Unity Biotechnology, Inc. | - USD | NaN% |
| Waters Corporation | 2.95 Billion USD | 100.0% |
| Biogen Inc. | 9.83 Billion USD | 100.0% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 100.0% |
| Evolus, Inc. | 202.08 Million USD | 100.0% |
| Adicet Bio, Inc. | - USD | NaN% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 100.0% |
| bluebird bio, Inc. | 29.49 Million USD | 100.0% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 100.0% |
| FibroGen, Inc. | 147.75 Million USD | 100.0% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 100.0% |
| Homology Medicines, Inc. | -6.65 Million USD | 100.0% |
| Geron Corporation | 237 Thousand USD | 100.0% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 100.0% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 100.0% |
| Myriad Genetics, Inc. | 678.4 Million USD | 100.0% |
| Viking Therapeutics, Inc. | - USD | NaN% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 100.0% |
| Zoetis Inc. | 8.54 Billion USD | 100.0% |
| Abeona Therapeutics Inc. | 3.5 Million USD | 100.0% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 100.0% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 100.0% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 100.0% |
| Kala Pharmaceuticals, Inc. | - USD | NaN% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 100.0% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | 100.0% |
| Verastem, Inc. | - USD | NaN% |
| Nektar Therapeutics | 90.12 Million USD | 100.0% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 100.0% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 100.0% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 100.0% |
| OPKO Health, Inc. | 863.49 Million USD | 100.0% |
| Exelixis, Inc. | 1.83 Billion USD | 100.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 100.0% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 100.0% |
| Anavex Life Sciences Corp. | - USD | NaN% |
| uniQure N.V. | 15.84 Million USD | 100.0% |
| Imunon, Inc. | - USD | NaN% |
| Blueprint Medicines Corporation | 249.38 Million USD | 100.0% |
| Insmed Incorporated | 305.2 Million USD | 100.0% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 100.0% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 100.0% |
| TG Therapeutics, Inc. | 233.66 Million USD | 100.0% |
| Incyte Corporation | 3.69 Billion USD | 100.0% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 100.0% |